

**Vaccine Adjuvants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants), By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants), By Application (Research Applications, Commercial Applications), By Region & Competition, 2020-2030F**

Market Report | 2025-03-24 | 180 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

**Report description:**

Global Vaccine Adjuvants Market was valued at USD 0.72 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.56% through 2030. The Global Vaccine Adjuvants Market is a critical component of the broader healthcare industry, playing a pivotal role in enhancing the efficacy of vaccines and bolstering global immunization efforts. Vaccine adjuvants are substances added to vaccines to stimulate a stronger and longer-lasting immune response, ultimately leading to improved protection against infectious diseases. This market has witnessed significant growth in recent years, driven by the increasing demand for vaccines to combat a wide range of diseases, including viral infections, bacterial illnesses, and emerging pandemics.

**Key Market Drivers**

**Rising Infectious Disease Threats**

The Global Vaccine Adjuvants Market is experiencing a notable upswing, and one of the primary driving forces behind this growth is the persistent and escalating threat posed by infectious diseases. In recent years, the world has witnessed a series of infectious disease outbreaks and pandemics that have underscored the critical importance of vaccination and vaccine adjuvants in safeguarding public health. These threats have led to a surge in demand for adjuvants, which play a pivotal role in enhancing the efficacy of vaccines and ensuring rapid and robust immune responses. For instance, according to the World Health Organization, infectious diseases are responsible for over 17 million deaths annually. Over the past two decades, 30 new infectious diseases have emerged, posing significant global health challenges and highlighting the urgent need for innovative prevention, treatment, and surveillance strategies.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott's-international.com](mailto:support@scott's-international.com)

[www.scott's-international.com](http://www.scott's-international.com)

## Key Market Challenges

### Regulatory Hurdles

One of the most formidable challenges for vaccine adjuvants is the arduous journey through the regulatory approval process. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require extensive preclinical and clinical data to demonstrate the safety and efficacy of new adjuvants. These rigorous requirements can significantly lengthen the timeline from development to market approval, delaying adjuvant availability and increasing development costs.

Regulatory requirements for vaccine adjuvants vary from one country or region to another. This lack of harmonization can create a complex and fragmented landscape for manufacturers seeking global approval. Adhering to multiple sets of regulations necessitates additional resources and can discourage investment in adjuvant research and development. Regulatory agencies often provide limited guidance or specific pathways for the approval of adjuvants. Manufacturers are left to navigate the regulatory process with minimal clear direction, which can result in uncertainty and potential missteps during development and submission. Clarity and consistent guidelines would be instrumental in streamlining the approval process.

### Key Market Trends

#### Expanding Consumer Markets

The Global Vaccine Adjuvants Market is experiencing a significant boost, thanks to the expansion of consumer markets across the globe. As public awareness about the importance of vaccines continues to grow, the demand for effective immunization has surged, propelling the need for vaccine adjuvants. Several factors contribute to the expansion of consumer markets and their positive impact on the vaccine adjuvants market. Rising global populations, particularly in emerging economies, are driving an increased demand for vaccines. As more people seek protection against infectious diseases, vaccine manufacturers are ramping up their production. Vaccine adjuvants play a pivotal role in enhancing the efficacy of vaccines, making them more attractive to a broader consumer base.

Furthermore, the prevalence of infectious diseases remains a global concern. Outbreaks and pandemics like the COVID-19 crisis have highlighted the critical need for vaccines to prevent and control the spread of diseases. This heightened awareness of infectious disease threats has motivated individuals and governments to invest in vaccination programs, further fueling the demand for adjuvanted vaccines.

### Key Market Players

- [ ] Dynavax Technologies
- [ ] Croda International Plc
- [ ] Gsk Plc
- [ ] Novavax
- [ ] Spi Pharma (A Subsidiary of Associated British Foods Plc)
- [ ] Agenus Inc.
- [ ] Phibro Animal Health Corporation
- [ ] Aurorium (Formerly Vertellus)
- [ ] Merck Kgaa
- [ ] Vaxine Pty Ltd

### Report Scope:

In this report, the Global Vaccine Adjuvants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

#### - [ ] Vaccine Adjuvants Market, By Product:

- o Adjuvant Emulsions
- o Pathogen Components
- o Saponin-Based Adjuvants
- o Particulate Adjuvants
- o Other Adjuvants

#### - [ ] Vaccine Adjuvants Market, By Type:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Human Vaccine Adjuvants
- o Veterinary Vaccine Adjuvants
- Vaccine Adjuvants Market, By Application:

- o Research Applications
- o Commercial Applications

- Vaccine Adjuvants Market, By Region:

- o North America

- United States

- Canada

- Mexico

- o Europe

- France

- United Kingdom

- Italy

- Germany

- Spain

- o Asia-Pacific

- China

- India

- Japan

- Australia

- South Korea

- o South America

- Brazil

- Argentina

- Colombia

- o Middle East & Africa

- South Africa

- Saudi Arabia

- UAE

- Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Adjuvants Market.

Available Customizations:

Global Vaccine Adjuvants Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

## **Table of Contents:**

1. Product Overview
  - 1.1. Market Definition
  - 1.2. Scope of the Market
    - 1.2.1. Markets Covered
    - 1.2.2. Years Considered for Study
    - 1.2.3. Key Market Segmentations
2. Research Methodology

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
  - 3.1. Overview of the Market
  - 3.2. Overview of Key Market Segmentations
  - 3.3. Overview of Key Market Players
  - 3.4. Overview of Key Regions/Countries
  - 3.5. Overview of Market Drivers, Challenges, Trends
4. Global Vaccine Adjuvants Market Outlook
  - 4.1. Market Size & Forecast
    - 4.1.1. By Value
  - 4.2. Market Share & Forecast
    - 4.2.1. By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants)
    - 4.2.2. By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants)
    - 4.2.3. By Application (Research Applications, Commercial Applications)
    - 4.2.4. By Region
    - 4.2.5. By Company (2024)
  - 4.3. Market Map
    - 4.3.1. By Product
    - 4.3.2. By Type
    - 4.3.3. By Application
    - 4.3.4. By Region
5. Asia Pacific Vaccine Adjuvants Market Outlook
  - 5.1. Market Size & Forecast
    - 5.1.1. By Value
  - 5.2. Market Share & Forecast
    - 5.2.1. By Product
    - 5.2.2. By Type
    - 5.2.3. By Application
    - 5.2.4. By Country
  - 5.3. Asia Pacific: Country Analysis
    - 5.3.1. China Vaccine Adjuvants Market Outlook
      - 5.3.1.1. Market Size & Forecast
        - 5.3.1.1.1. By Value
        - 5.3.1.1.2. Market Share & Forecast
          - 5.3.1.2.1. By Product
          - 5.3.1.2.2. By Type
          - 5.3.1.2.3. By Application
      - 5.3.2. India Vaccine Adjuvants Market Outlook
        - 5.3.2.1. Market Size & Forecast
          - 5.3.2.1.1. By Value
        - 5.3.2.2. Market Share & Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.2.2.1. By Product
- 5.3.2.2.2. By Type
- 5.3.2.2.3. By Application
- 5.3.3. Australia Vaccine Adjuvants Market Outlook
  - 5.3.3.1. Market Size & Forecast
    - 5.3.3.1.1. By Value
  - 5.3.3.2. Market Share & Forecast
    - 5.3.3.2.1. By Product
    - 5.3.3.2.2. By Type
    - 5.3.3.2.3. By Application
- 5.3.4. Japan Vaccine Adjuvants Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Product
    - 5.3.4.2.2. By Type
    - 5.3.4.2.3. By Application
- 5.3.5. South Korea Vaccine Adjuvants Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Product
    - 5.3.5.2.2. By Type
    - 5.3.5.2.3. By Application
- 6. Europe Vaccine Adjuvants Market Outlook
  - 6.1. Market Size & Forecast
    - 6.1.1. By Value
  - 6.2. Market Share & Forecast
    - 6.2.1. By Product
    - 6.2.2. By Type
    - 6.2.3. By Application
    - 6.2.4. By Country
  - 6.3. Europe: Country Analysis
    - 6.3.1. France Vaccine Adjuvants Market Outlook
      - 6.3.1.1. Market Size & Forecast
        - 6.3.1.1.1. By Value
      - 6.3.1.2. Market Share & Forecast
        - 6.3.1.2.1. By Product
        - 6.3.1.2.2. By Type
        - 6.3.1.2.3. By Application
    - 6.3.2. Germany Vaccine Adjuvants Market Outlook
      - 6.3.2.1. Market Size & Forecast
        - 6.3.2.1.1. By Value
      - 6.3.2.2. Market Share & Forecast
        - 6.3.2.2.1. By Product
        - 6.3.2.2.2. By Type
        - 6.3.2.2.3. By Application

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.3.3. Spain Vaccine Adjuvants Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Type
    - 6.3.3.2.3. By Application
- 6.3.4. Italy Vaccine Adjuvants Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Product
    - 6.3.4.2.2. By Type
    - 6.3.4.2.3. By Application
- 6.3.5. United Kingdom Vaccine Adjuvants Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Product
    - 6.3.5.2.2. By Type
    - 6.3.5.2.3. By Application
- 7. North America Vaccine Adjuvants Market Outlook
  - 7.1. Market Size & Forecast
    - 7.1.1. By Value
  - 7.2. Market Share & Forecast
    - 7.2.1. By Product
    - 7.2.2. By Type
    - 7.2.3. By Application
    - 7.2.4. By Country
  - 7.3. North America: Country Analysis
    - 7.3.1. United States Vaccine Adjuvants Market Outlook
      - 7.3.1.1. Market Size & Forecast
        - 7.3.1.1.1. By Value
      - 7.3.1.2. Market Share & Forecast
        - 7.3.1.2.1. By Product
        - 7.3.1.2.2. By Type
        - 7.3.1.2.3. By Application
    - 7.3.2. Mexico Vaccine Adjuvants Market Outlook
      - 7.3.2.1. Market Size & Forecast
        - 7.3.2.1.1. By Value
      - 7.3.2.2. Market Share & Forecast
        - 7.3.2.2.1. By Product
        - 7.3.2.2.2. By Type
        - 7.3.2.2.3. By Application
    - 7.3.3. Canada Vaccine Adjuvants Market Outlook
      - 7.3.3.1. Market Size & Forecast
        - 7.3.3.1.1. By Value

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.3.3.2. Market Share & Forecast
  - 7.3.3.2.1. By Product
  - 7.3.3.2.2. By Type
  - 7.3.3.2.3. By Application
- 8. South America Vaccine Adjuvants Market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Product
    - 8.2.2. By Type
    - 8.2.3. By Application
    - 8.2.4. By Country
  - 8.3. South America: Country Analysis
    - 8.3.1. Brazil Vaccine Adjuvants Market Outlook
      - 8.3.1.1. Market Size & Forecast
        - 8.3.1.1.1. By Value
      - 8.3.1.2. Market Share & Forecast
        - 8.3.1.2.1. By Product
        - 8.3.1.2.2. By Type
        - 8.3.1.2.3. By Application
    - 8.3.2. Argentina Vaccine Adjuvants Market Outlook
      - 8.3.2.1. Market Size & Forecast
        - 8.3.2.1.1. By Value
      - 8.3.2.2. Market Share & Forecast
        - 8.3.2.2.1. By Product
        - 8.3.2.2.2. By Type
        - 8.3.2.2.3. By Application
    - 8.3.3. Colombia Vaccine Adjuvants Market Outlook
      - 8.3.3.1. Market Size & Forecast
        - 8.3.3.1.1. By Value
      - 8.3.3.2. Market Share & Forecast
        - 8.3.3.2.1. By Product
        - 8.3.3.2.2. By Type
        - 8.3.3.2.3. By Application
  - 9. Middle East and Africa Vaccine Adjuvants Market Outlook
    - 9.1. Market Size & Forecast
      - 9.1.1. By Value
    - 9.2. Market Share & Forecast
      - 9.2.1. By Product
      - 9.2.2. By Type
      - 9.2.3. By Application
      - 9.2.4. By Country
    - 9.3. MEA: Country Analysis
      - 9.3.1. South Africa Vaccine Adjuvants Market Outlook
        - 9.3.1.1. Market Size & Forecast
          - 9.3.1.1.1. By Value
        - 9.3.1.2. Market Share & Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Type
- 9.3.1.2.3. By Application
- 9.3.2. Saudi Arabia Vaccine Adjuvants Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Type
    - 9.3.2.2.3. By Application
- 9.3.3. UAE Vaccine Adjuvants Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Type
    - 9.3.3.2.3. By Application
- 9.3.4. Egypt Vaccine Adjuvants Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Product
    - 9.3.4.2.2. By Type
    - 9.3.4.2.3. By Application
- 10. Market Dynamics
  - 10.1. Drivers
  - 10.2. Challenges
- 11. Market Trends & Developments
  - 11.1. Recent Developments
  - 11.2. Product Launches
  - 11.3. Mergers & Acquisitions
- 12. Global Vaccine Adjuvants Market: SWOT Analysis
- 13. Porter's Five Forces Analysis
  - 13.1. Competition in the Industry
  - 13.2. Potential of New Entrants
  - 13.3. Power of Suppliers
  - 13.4. Power of Customers
  - 13.5. Threat of Substitute Product
- 14. Competitive Landscape
  - 14.1. Dynavax Technologies
    - 14.1.1. Business Overview
    - 14.1.2. Company Snapshot
    - 14.1.3. Products & Services
    - 14.1.4. Financials (In case of listed)
    - 14.1.5. Recent Developments
    - 14.1.6. SWOT Analysis
  - 14.2. Croda International Plc

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.3. Gsk Plc
- 14.4. Novavax
- 14.5. Spi Pharma (A Subsidiary of Associated British Foods Plc)
- 14.6. Agenus Inc.
- 14.7. Phibro Animal Health Corporation
- 14.8. Aurorium (Formerly Vertellus)
- 14.9. Merck Kgaa
- 14.10. Vaxine Pty Ltd.
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Vaccine Adjuvants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants), By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants), By Application (Research Applications, Commercial Applications), By Region & Competition, 2020-2030F**

Market Report | 2025-03-24 | 180 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Multi-User License	\$5500.00
	Custom Research License	\$8000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-11"/>
		Signature	<input type="text"/>